Iovance BiotherapeuticsIOVA
IOVA
About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Employees: 838
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 34
19% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 84
6% more funds holding
Funds holding: 283 [Q3] → 299 (+16) [Q4]
1.98% more ownership
Funds ownership: 77.24% [Q3] → 79.22% (+1.98%) [Q4]
19% less capital invested
Capital invested by funds: $2.2B [Q3] → $1.79B (-$417M) [Q4]
21% less call options, than puts
Call options by funds: $28.9M | Put options by funds: $36.4M
22% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 7 (-2) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
63%
upside
Avg. target
$17.71
479%
upside
High target
$32
946%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Goldman Sachs Andrea Tan 44% 1-year accuracy 4 / 9 met price target | 423%upside $16 | Buy Maintained | 17 Apr 2025 |
Barclays Peter Lawson 5% 1-year accuracy 1 / 21 met price target | 63%upside $5 | Overweight Maintained | 14 Apr 2025 |
Truist Securities Asthika Goonewardene 22% 1-year accuracy 5 / 23 met price target | 390%upside $15 | Buy Maintained | 3 Mar 2025 |
Chardan Capital Geulah Livshits 7% 1-year accuracy 4 / 60 met price target | 880%upside $30 | Buy Maintained | 3 Mar 2025 |
Baird Michael Ulz 20% 1-year accuracy 4 / 20 met price target | 554%upside $20 | Outperform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 8 articles about IOVA published over the past 30 days
Positive
The Motley Fool
14 hours ago
This Biotech Stock Could Be the Best Investment of the Decade
Picking stocks with a relatively narrow timeframe in mind -- and with a particular performance expectation -- can be tricky. Most investors can distinguish between bad, good, and even-better investment prospects.
Neutral
GlobeNewsWire
1 day ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 297,600 shares of Iovance's common stock to fifty new, non-executive employees.
Neutral
The Motley Fool
5 days ago
Is Iovance Biotherapeutics a Millionaire-Maker?
Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money.
Positive
The Motley Fool
1 week ago
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
Positive
Benzinga
3 weeks ago
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Positive
The Motley Fool
4 weeks ago
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
Positive
The Motley Fool
4 weeks ago
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery.
Neutral
GlobeNewsWire
4 weeks ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 308,710 shares of Iovance's common stock to forty-three new, non-executive employees.
Negative
The Motley Fool
1 month ago
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.
Negative
Seeking Alpha
1 month ago
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showed mixed results, with $42.1M and $48.7M in Amtagvi revenues, respectively, and a notable cash burn. Despite high costs and competition, Amtagvi remains a preferred option in PD-1-refractory melanoma, with plans to increase its price for better margins.
Charts implemented using Lightweight Charts™